Garratty G (1988) Immune hemolytic anemia induced by drugs. PatholBiol (Paris) 36(10):1237–1245

Google Scholar 

Bub CB, Reis IND, Aravechia MG, Santos LD et al (2018) Transfusion management for patients taking an anti-CD38 monoclonal antibody. Rev Bras HematolHemoter 40(1):25–29

Google Scholar 

Nedumcheril MT, DeSimone RA, Racine-Brzostek SE et al (2021) Overcoming Drug Interference in Transfusion Testing: A Spotlight on Daratumumab. J Blood Med 12:327–336

Article  PubMed  PubMed Central  Google Scholar 

Mehta K, Shahid U, Malavasi F (1996) Human CD38, a cell-surface protein with multiple functions. FASEB J 10(12):1408–1417

Article  CAS  PubMed  Google Scholar 

Oostendorp M, Lammerts van Bueren JJ, Doshi P et al (2015) When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy. Transfusion 55(6 Pt 2):1555–62

Article  PubMed  Google Scholar 

Chari A, Arinsburg S, Jagannath S et al (2018) Blood transfusion management and transfusion-related outcomes in daratumumab-treated patients with relapsed or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 18(1):44–51

Article  PubMed  Google Scholar 

Cohn CS, Delaney M, Johnson ST et al (2020) Technical manual, 20th edn. AABB, Bethesda

Google Scholar 

Clark CA, Cornell RF, Scott EC, Chung J, Costa LJ (2016) Management of relapsed and refractory multiple myeloma in modern times: Incorporating new agents into decision-making. Am J Hematol 91(10):1044–1051

Article  PubMed  Google Scholar 

Chapuy CI, Kaufman RM, Alyea EP et al (2018) Daratumumab for delayed red-cell engraftment after allogeneic transplantation. N Engl J Med. 379(19):1846–50

Article  CAS  PubMed  Google Scholar 

Mirgh S, Ahmed R, Agrawal N et al (2019) Will daratumumab be the next game changer in early thymic precursor-acute lymphoblastic leukaemia? Br J Haematol 187(2):e33–e35

Article  PubMed  Google Scholar 

Ejaz K, Roback JD, Stowell SR et al (2021) Daratumumab: Beyond Multiple Myeloma. Transfus Med Rev 35(3):36–43

Article  PubMed  Google Scholar 

Chapuy CI, Nicholson RT, Aguad MD et al (2015) Resolving the daratumumab interference with blood compatibility testing. Transfusion 55(6 Pt 2):1545–1554

Article  CAS  PubMed  Google Scholar 

Sullivan HC, Gerner-Smidt C, Nooka AK et al (2017) Daratumumab (anti-CD38) induces loss of CD38 on red blood cells. Blood 129(22):3033–7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chapuy CI, Aguad MD, Nicholson RT et al (2016) International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing. Transfusion 56(12):2964–2972

Article  CAS  PubMed  Google Scholar 

Hosokawa M, Kashiwagi H, Nakayama K et al (2018) Distinct effects of daratumumab on indirect and direct antiglobulin tests: a new method employing 0.01 mol/L dithiothreitolfor negating the daratumumab interference with preserving K antigenicity (Osaka method). Transfusion. 58(12):3003–13

Article  CAS  PubMed  Google Scholar 

Anani WQ, Marchan MG, Bensing KM et al (2017) Practical approaches and costs for provisioning safe transfusions during anti-CD38 therapy. Transfusion 57(6):1470–1479

Article  CAS  PubMed  Google Scholar 

Carreno-Tarragona G, Cedena T, Montejano L et al (2019) Papain-treated panels are a simple method for the identification of alloantibodies in multiple myeloma patients treated with anti-CD38-basedtherapies. Transfus Med 29(3):193–196

Article  CAS  PubMed  Google Scholar 

Ye Z, Wolf LA, Mettman D, Plapp FV (2020) Risk of RBC alloimmunization in multiple myeloma patients treated by Daratumumab. Vox Sang 115(2):207–212

Article  CAS  PubMed  Google Scholar 

Lonial S, Weiss BM, Usmani SZ et al (2016) Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 387(10027):1551–1560

Article  CAS  PubMed  Google Scholar